-DOCSTART- -X- O
Acute -X- _ O
gastroenteritis -X- _ O
, -X- _ O
characterized -X- _ O
by -X- _ O
the -X- _ O
onset -X- _ O
of -X- _ O
diarrhea -X- _ O
with -X- _ O
or -X- _ O
without -X- _ O
vomiting -X- _ O
, -X- _ O
continues -X- _ O
to -X- _ O
be -X- _ O
a -X- _ O
major -X- _ O
cause -X- _ O
of -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
in -X- _ O
children -X- _ O
in -X- _ O
mostly -X- _ O
resource-constrained -X- _ O
nations. -X- _ O
Although -X- _ O
generally -X- _ O
a -X- _ O
mild -X- _ O
and -X- _ O
self-limiting -X- _ O
disease -X- _ O
, -X- _ O
gastroenteritis -X- _ O
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
most -X- _ O
common -X- _ O
causes -X- _ O
of -X- _ O
hospitalization -X- _ O
and -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
a -X- _ O
substantial -X- _ O
disease -X- _ O
burden. -X- _ O
Worldwide -X- _ O
, -X- _ O
up -X- _ O
to -X- _ O
40 -X- _ O
% -X- _ O
of -X- _ O
children -X- _ O
aged -X- _ O
less -X- _ O
than -X- _ O
5 -X- _ O
years -X- _ O
with -X- _ O
diarrhea -X- _ O
are -X- _ O
hospitalized -X- _ O
with -X- _ O
rotavirus. -X- _ O
Also -X- _ O
, -X- _ O
some -X- _ O
microorganisms -X- _ O
have -X- _ O
been -X- _ O
found -X- _ O
predominantly -X- _ O
in -X- _ O
resource-constrained -X- _ O
nations -X- _ O
, -X- _ O
including -X- _ O
Shigella -X- _ O
spp -X- _ O
, -X- _ O
Vibrio -X- _ O
cholerae -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
protozoan -X- _ O
infections. -X- _ O
Prevention -X- _ O
remains -X- _ O
essential -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
rotavirus -X- _ B-Outcome
vaccines -X- _ I-Outcome
have -X- _ I-Outcome
demonstrated -X- _ I-Outcome
good -X- _ I-Outcome
safety -X- _ I-Outcome
and -X- _ I-Outcome
efficacy -X- _ I-Outcome
profiles -X- _ I-Outcome
in -X- _ I-Outcome
large -X- _ I-Outcome
clinical -X- _ I-Outcome
trials. -X- _ I-Outcome
Because -X- _ O
dehydration -X- _ O
is -X- _ O
the -X- _ O
major -X- _ O
complication -X- _ O
associated -X- _ O
with -X- _ O
gastroenteritis -X- _ O
, -X- _ O
appropriate -X- _ B-Outcome
fluid -X- _ I-Outcome
management -X- _ I-Outcome
( -X- _ I-Outcome
oral -X- _ I-Outcome
or -X- _ I-Outcome
intravenous -X- _ I-Outcome
) -X- _ I-Outcome
is -X- _ I-Outcome
an -X- _ I-Outcome
effective -X- _ I-Outcome
and -X- _ I-Outcome
safe -X- _ I-Outcome
strategy -X- _ I-Outcome
for -X- _ I-Outcome
rehydration. -X- _ I-Outcome
Continuation -X- _ I-Outcome
of -X- _ I-Outcome
breastfeeding -X- _ I-Outcome
is -X- _ I-Outcome
strongly -X- _ I-Outcome
recommended. -X- _ I-Outcome
New -X- _ I-Outcome
treatments -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
antiemetics -X- _ I-Outcome
( -X- _ I-Outcome
ondansetron -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
some -X- _ I-Outcome
antidiarrheal -X- _ I-Outcome
agents -X- _ I-Outcome
( -X- _ I-Outcome
racecadotril -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
chemotherapeutic -X- _ I-Outcome
agents -X- _ I-Outcome
are -X- _ I-Outcome
often -X- _ I-Outcome
proposed -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
yet -X- _ I-Outcome
universally -X- _ I-Outcome
recommended. -X- _ I-Outcome
Probiotics -X- _ I-Outcome
, -X- _ I-Outcome
also -X- _ I-Outcome
known -X- _ I-Outcome
as -X- _ I-Outcome
“food -X- _ I-Outcome
supplement -X- _ I-Outcome
, -X- _ I-Outcome
” -X- _ I-Outcome
seem -X- _ I-Outcome
to -X- _ I-Outcome
improve -X- _ I-Outcome
intestinal -X- _ I-Outcome
microbial -X- _ I-Outcome
balance -X- _ I-Outcome
, -X- _ I-Outcome
reducing -X- _ I-Outcome
the -X- _ I-Outcome
duration -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
severity -X- _ I-Outcome
of -X- _ I-Outcome
acute -X- _ I-Outcome
infectious -X- _ I-Outcome
diarrhea. -X- _ I-Outcome
The -X- _ O
European -X- _ O
Society -X- _ O
for -X- _ O
Paediatric -X- _ O
Gastroenterology -X- _ O
, -X- _ O
Hepatology -X- _ O
and -X- _ O
Nutrition -X- _ O
and -X- _ O
the -X- _ O
European -X- _ O
Society -X- _ O
of -X- _ O
Paediatric -X- _ O
Infectious -X- _ O
Diseases -X- _ O
guidelines -X- _ O
make -X- _ O
a -X- _ O
stronger -X- _ O
recommendation -X- _ O
for -X- _ O
the -X- _ O
use -X- _ B-Outcome
of -X- _ I-Outcome
probiotics -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
management -X- _ I-Outcome
of -X- _ I-Outcome
acute -X- _ I-Outcome
gastroenteritis -X- _ I-Outcome
, -X- _ O
particularly -X- _ O
those -X- _ O
with -X- _ O
documented -X- _ O
efficacy -X- _ O
such -X- _ O
as -X- _ O
Lactobacillus -X- _ O
rhamnosus -X- _ O
GG -X- _ O
, -X- _ O
Lactobacillus -X- _ B-Outcome
reuteri -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
Saccharomyces -X- _ I-Outcome
boulardii. -X- _ I-Outcome
To -X- _ O
date -X- _ O
, -X- _ O
the -X- _ O
management -X- _ O
of -X- _ O
acute -X- _ O
gastroenteritis -X- _ O
has -X- _ O
been -X- _ O
based -X- _ O
on -X- _ O
the -X- _ O
option -X- _ O
of -X- _ O
“doing -X- _ O
the -X- _ O
least” -X- _ O
: -X- _ O
oral -X- _ B-Outcome
rehydration-solution -X- _ I-Outcome
administration -X- _ I-Outcome
, -X- _ I-Outcome
early -X- _ I-Outcome
refeeding -X- _ I-Outcome
, -X- _ I-Outcome
no -X- _ I-Outcome
testing -X- _ I-Outcome
, -X- _ I-Outcome
no -X- _ I-Outcome
unnecessary -X- _ I-Outcome
drugs -X- _ I-Outcome
. -X- _ O

